Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKTR-102 vs Irinotecan in KRAS-Mutant mCRC
NCT00856375Phase 2Completed
- Sponsor
- Nektar Therapeutics
- Start
- Dec 2008
- Primary completion
- Jul 2014
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of etirinotecan pegol in metastatic colorectal cancer (mCRC), sponsored by Nektar Therapeutics. Started Dec 2008; status: completed.
02
Drugs
etirinotecan pegol
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00856375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00856375.